ChemDiv Beyond the Flatland 3D-Fragment Library for Fragment-Based Drug Discovery (FBDD)

Similar documents
Enamine Golden Fragment Library

AMRI COMPOUND LIBRARY CONSORTIUM: A NOVEL WAY TO FILL YOUR DRUG PIPELINE

György M. Keserű H2020 FRAGNET Network Hungarian Academy of Sciences

Introduction. OntoChem

Using AutoDock for Virtual Screening

Introduction to Chemoinformatics and Drug Discovery

Important Aspects of Fragment Screening Collection Design

Advanced Medicinal Chemistry SLIDES B

Design and Synthesis of the Comprehensive Fragment Library

Synthetic organic compounds

Computational Methods and Drug-Likeness. Benjamin Georgi und Philip Groth Pharmakokinetik WS 2003/2004

Synthetic organic compounds

Increasing the Coverage of Medicinal Chemistry-Relevant Space in Commercial Fragments Screening

Introduction to FBDD Fragment screening methods and library design

Implementation of novel tools to facilitate fragment-based drug discovery by NMR:

Computational Chemistry in Drug Design. Xavier Fradera Barcelona, 17/4/2007

Biologically Relevant Molecular Comparisons. Mark Mackey

COMBINATORIAL CHEMISTRY: CURRENT APPROACH

Computational chemical biology to address non-traditional drug targets. John Karanicolas

Virtual Screening: How Are We Doing?

Virtual Libraries and Virtual Screening in Drug Discovery Processes using KNIME

Retrieving hits through in silico screening and expert assessment M. N. Drwal a,b and R. Griffith a

Navigation in Chemical Space Towards Biological Activity. Peter Ertl Novartis Institutes for BioMedical Research Basel, Switzerland

Design and Synthesis of 3-Dimensional Fragments to Explore Pharmaceutical Space

BIOVIA ENHANCED STEREOCHEMICAL REPRESENTATION WHITE PAPER

Receptor Based Drug Design (1)

Reaxys Medicinal Chemistry Fact Sheet

Partial Periodic Table

EMPIRICAL VS. RATIONAL METHODS OF DISCOVERING NEW DRUGS

Applications of Fragment Based Approaches

COMBINATORIAL CHEMISTRY IN A HISTORICAL PERSPECTIVE

Ignasi Belda, PhD CEO. HPC Advisory Council Spain Conference 2015

Building innovative drug discovery alliances

Relative Drug Likelihood: Going beyond Drug-Likeness

DRUG DISCOVERY TODAY ELN ELN. Chemistry. Biology. Known ligands. DBs. Generate chemistry ideas. Check chemical feasibility In-house.

Dr. Sander B. Nabuurs. Computational Drug Discovery group Center for Molecular and Biomolecular Informatics Radboud University Medical Centre

The Changing Requirements for Informatics Systems During the Growth of a Collaborative Drug Discovery Service Company. Sally Rose BioFocus plc

Unlocking the potential of your drug discovery programme

"Pip tazo" is a nickname given to a popular combination of antibiotics prescribed for a variety of infections. A.

Hit to Lead Michael Rafferty

Dock Ligands from a 2D Molecule Sketch

DivCalc: A Utility for Diversity Analysis and Compound Sampling

Early Stages of Drug Discovery in the Pharmaceutical Industry

Use of data mining and chemoinformatics in the identification and optimization of high-throughput screening hits for NTDs

KNIME-based scoring functions in Muse 3.0. KNIME User Group Meeting 2013 Fabian Bös

CH MEDICINAL CHEMISTRY

Automated Compound Collection Enhancement: how Pipeline Pilot preserved our sanity. Darren Green GSK

HO HO. 1) BH 3 HCl. + enantiomer either one may be drawn 4. + enantiomer either one may be drawn 4 1) O 3

Rules for drug discovery: can simple property criteria help you to find a drug?

NMR Solutions for drug discovery

Structural biology and drug design: An overview

In Silico Investigation of Off-Target Effects

Drug Informatics for Chemical Genomics...

User Guide for LeDock

Hydrogen Bonding & Molecular Design Peter

Medicinal Chemist s Relationship with Additivity: Are we Taking the Fundamentals for Granted?

Return on Investment in Discovery Chiral Separations

Reaxys The Highlights

If Compound 2 (below) was used in the above reaction, how might things change? Name Page 1. I. (23 points)

Fragment based drug discovery in teams of medicinal and computational chemists. Carsten Detering

Virtual screening for drug discovery. Markus Lill Purdue University

Introduction to Fragment-based Drug Discovery

A powerful site for all chemists CHOICE CRC Handbook of Chemistry and Physics

O N N. electrons in ring

SCH 302. Tutorial PART B ORGANIC SYNTHESIS

BioSolveIT. A Combinatorial Approach for Handling of Protonation and Tautomer Ambiguities in Docking Experiments

Stereodivergent Catalysis. Aragorn Laverny SED Group Meeting July

Fragment-based drug discovery

Medicinal Chemistry and Chemical Biology

FRAGMENT SCREENING IN LEAD DISCOVERY BY WEAK AFFINITY CHROMATOGRAPHY (WAC )

Lead- and drug-like compounds: the rule-of-five revolution

Supporting Information (Part II) for ACS Combinatorial Science

The use of Design of Experiments to develop Efficient Arrays for SAR and Property Exploration

Structure based drug design and LIE models for GPCRs

PerspectiVe. Recent Developments in Fragment-Based Drug Discovery. 1. Introduction. 2. Trends and Developments

Capturing Chemistry. What you see is what you get In the world of mechanism and chemical transformations

Partial Periodic Table

Chemical library design

Final Exam /340 ( CHEM 6352 Fall %) Name

Quantum Mechanical Models of P450 Metabolism to Guide Optimization of Metabolic Stability

Partial Periodic Table

ChemBioNet: Chemical Biology supported by Networks of Chemists and Biologists. Affinity Proteomics Meeting Alpbach. Michael Lisurek 15.3.

Next Generation Computational Chemistry Tools to Predict Toxicity of CWAs

Experiment : Reduction of Ethyl Acetoacetate

Targeting protein-protein interactions: A hot topic in drug discovery

CHEMISTRY 121 PRACTICE EXAM 2

NMR methods in fragment screening: theory and a comparison with other biophysical techniques

1. methyl 2. methylene 3. methine 4. primary 5. secondary 6. tertiary 7. quarternary 8. isopropyl

Chapter 6. Isomers and Stereochemistry

Chemical Space. Space, Diversity, and Synthesis. Jeremy Henle, 4/23/2013

Structural Bioinformatics (C3210) Molecular Docking

BioSolveIT. A Combinatorial Docking Approach for Dealing with Protonation and Tautomer Ambiguities

A graph based approach to construct target focused libraries for virtual screening

"Pip tazo" is a nickname given to a popular combination of antibiotics prescribed for a variety of infections. A.

CH 3 C 2 H 5. Tetrahedral Stereochemistry

Structure-Based Drug Discovery An Overview

CSD. CSD-Enterprise. Access the CSD and ALL CCDC application software

Fall Organic Chemistry Experiment #6 Fractional Crystallization (Resolution of Enantiomers)

Fragment Screening in Drug Discovery

Bridging the Dimensions:

Transcription:

ChemDiv Beyond the Flatland 3D-Fragment Library for Fragment-Based Drug Discovery (FBDD)

CEMDIV BEYD TE FLATLAD 3D-FRAGMET LIBRARY BACKGRUD Fragment-based drug discovery (FBDD) has become an efficient methodology toward identification of small-molecule leads [1-3], and therefore fragment libraries are of great interest in both industry and academia. The majority of commercially available fragment libraries are predominantly populated with flat (hetero)aromatic chemotypes [4, ]. This can be explained by two factors. Initially, fragment libraries were designed to be well detectable in MR screening. Since (hetero)aromatic compounds usually exhibit well resolved chemical shifts, they are MR friendly fragments for hit identification [6]. In addition, a large number of fragment hits have been reported against kinase ATP-binding pocket. Since such fragment hits should mimic the adenine base of ATP, almost all of them can be characterized as flat sp 2 -rich structures. n the other hand, nature is three-dimensional and therefore recognizes small molecules in a complementary 3Dfashion, and so drugs are likely to be more selective for their targets if they are three-dimensional too [7, 8]. ot coincidentally, compounds with diverse and well-developed 3D-shapes have become the most attractive ones on the market of screening compounds for TS for last several years. Furthermore, Fsp 3 parameter has become one of the most important criterion of TS libraries value since it was introduced in 29 by Frank Lovering et.al [9] as a measure of three-dimensionality and therefore complexity for libraries members. According to their findings and our further observations, scaffold/molecule saturation may benefit: More diversity; More complexity; Access to greater chemical space; Improved phys-chem parameters (logp; PSA; water solubility etc.); More opportunity to reduce scaffold MW; More opportunity for further scaffold modification; atural product-likeness; Better affinity to target proteins and greater selectivity; Easy access to IP-clean field. oteworthy, this trend retained almost unnoticed on FBDD field until recently perhaps because complexity of such compounds contradicts main principle of FBDD from simplest fragments toward complex ligands. evertheless, the authors of numerous recent discussion papers are convinced that chemical space and quality of current fragment libraries will be improved significantly if their 3D-diversity is enriched. In their opinion, this can expand the horizons of FBDD enabling new opportunities in most challenging target classes such as PPI, β-secretase etc [3-6,1]. Some research groups have made first practical contribution on this direction [8,11]. Furthermore, several UK-based nonprofit drug discovery institutions, spanning a range of therapeutic foci, have come together to form the 3D Fragment Consortium (http://www.3dfrag.org) aiming to build a shared fragment library with enhanced three-dimensional characteristics and subsequently evaluate them in a range of fragment screens using a variety of screening methodologies. Taking into account this trend on FBDD field we at ChemDiv have built our own Beyond the Flatland 3D-Fragment Library.

STRATEGY F LIBRARY MEMBERS SELECTI The library candidates should meet at least one of the following criteria: Fsp3.4, preferably due to higher saturation of (hetero)cycle but not side chains; ne and more chiral center in structures; Bridged structures; Spiro-structures; 1,2-Di (bulky)substituted (hetero)cycles The following filters have been applied for final library population: MW 3; clogp 3.; BD ; BA 8; RB 4; o Med-Chem restrictions (widely used and proprietary ChemDiv substructure filters on reactive functionalities, toxicophores, instability suspicions etc.) LIBRARY SUMMARY The library consists of more than 4,4 fragments; Assured chemical diversity (diversity coefficient.9); More than 11 compounds meet strict Astex Rule of Three criteria [12] (MW 3, clogp 3, -bond donors 3, -bond acceptors 3); More than 28 library members contain at least one chiral center in the structure; More than 2 bridged fragmens; More than 4 spiro-fragments. Key Phys-Chem Parameters for Beyond the Flatland 3D-Fragment Library are represented in Table 1.

Table 1. Phys-Chem Parameters for Beyond the Flatland 3D-Fragment Library Phys-Chem Parameter Range for 3D-FL Average for 3D-FL MW 111 3 264 clogp -2.8...3. 1.22 RB 4 2.64 BA 8 4. BD.9 PSA 3.2 18.3 6.4 Fsp 3.6 1..8 Chiral centers 1 clogd (p 7.4) -6.8. 1. clogsw (p 7.4) -8.3.4-2.1 READIESS FR IT T LEAD FLLW-UP The key feature of our BF-3D-fragment library is that more than 9% of the library members have arisen from ChemDiv s DS program. This means: Majority of fragments belong some specific scaffolds, so each of these scaffolds is represented in BF-3Dfragment library by small sets of fragments that are ready for preliminary SAR; Usually these scaffolds are represented also in our stock-available TS-library that can be used for further advanced SAR; Based on these scaffolds additional sub-libraries can be designed and synthesized upon request; These scaffolds contain at least two points of variability and very often they can be modified into another chemotypes. All listed above make our fragments ready for easy hit to lead follow-up if some hits are found. STERECEMISTRY TES We track carefully stereochemistry of the library members, so we provide stereochemical information for all of them. For compounds with one and more chiral centers in structure we usually deliver racemates. owever, in some cases (e.g. compounds arisen from nature products) we provide pure enantiomers. Their absolute configuration is as drawn with up/down wedges, and structures are marked with chirality flag in db/sdf.

For compounds with two and more chiral centers we deliver pure diastereomer as a racemic mixture (if chirality flag is not applied). Relative configurations are shown with up/down wedges. The relative configuration for scaffolds or singletons has been assigned by at least one of the following: - Literature data for reported compounds - Reported reaction mechanisms and/or stereochemical outcome for stereo-controlled reactions - Spectral data (2D-MR, X-Ray). SELECTED EXAMPLES F 3D-FRAGMETS Examples of spiro-fragments (approx. 4 library members): 2 S

Examples of bridged fragments (approx. 2 library members): F F BEYD TE FLATLAD 3D-FRAGMET LIBRARY vs CEMDIV CVETIAL FRAGMET LIBRARY In contrast to predominantly flat ChemDiv conventional fragment library (14.3K members, see separate description), more than 8% of 3D-library members have Fsp3.4. Distribution of fragments by Fsp 3 parameter for both libraries is represented in Fig. 1. % of Compounds 4 4 3 3 2 2 1 1.2.2.4.4.6.6.8.8 1. Fsp BF-3D-FL Conventional FL 3 Fig. 1.

We have compared the main characteristics of both libraries and found that the 3D-library is more attractive in terms of both, 2D- and 3D-diversity. Thus, diversity coefficient [13] for 3D-library is.9 vs.87 for conventional one. For distribution of the libraries members by diversity see Fig.2. % of Compounds 3 2 2 1 1.86.88.9.92.94.96 BF-3D-FL Conventional FL.98 1. Diversity Fig. 2. Plots of Principal Moments of Inertia (PMI) [14] clearly illustrate significantly increased three-dimensionality and 3Dshape diversity for 3D-library members (Fig 3a) if compare to conventional library (Fig. 3b). 3D-FL PR2 1.9.9.8.8.7.7.6.6. PR1. Fig. 3a..1.2.3.4..6.7.8.9 1

Conventional FL 1.9.9.8.8.7.7.6.6...1.2.3.4..6.7.8.9 1 Fig. 3b. igher degree of saturation (Fsp3) affects favorably on the physico-chemical parameters of 3D-library. Thus, 16% of conventional library lie in pharmacologically unfavorable range of PSA ( 8), whereas 3D-library contains only 9.% of such fragments. For distribution the libraries member by PSA see Fig. 4. 4 4 % of Compounds 3 3 2 2 1 1 2 2 4 4 6 BF-3D-FL 6 8 Conventional FL 8 1 >1 PSA Fig. 4. Represented below charts demonstrate clearly the improvement in important parameters such as clogp (Fig. ), clogd (Fig. 6), and, the most importantly, water solubility clogsw (Fig. 7).

2 2 % of compounds 1 1 less -. -.....,,...1. 1...1. 1...2. 2...2. 2. 3. clogp BF-3D-FL Conventional FL Fig.. 3 3 2 % of Compounds 2 1 1-6...-2-2...-1-1 1 1 2 2 3 3 4 4... clogd BF-3D-FL Conventional FL Fig. 6. Finally, 3D-library is more water soluble : almost 7% of its members have clogsw 3. whereas there are only % of conventional library lie in this range.

3 2 % of Compounds 2 1 1-7 -6-6...- -...-4-4...-3-3...-2-2...-1-1......1 1...2 2 6 LogSW BF-3D-Library Conventional FL FURTER IFRMATI We provide structure data file (MDL sdf or db ) or SMILE upon request; You can choose entire library or set of selected fragments; we will be happy to assist you with selection (e.g. by applying custom filters, by core diversity etc,); All fragments are available in 1 mg quantities and can be delivered as custom weighted dry powders or as solutions in DMS. Custom formatting is available; We provide analytical data with all orders. REFERECES 1. Congreve M, Chessari G, Tisi D, Woodhead A.J. Recent developments in fragment-based drug discovery. J. Med. Chem. 1, 3661 368 (28). 2. Murray C.W, Rees D.C The rise of fragment-based drug discovery. at. Chem. 1, 187 192 (29). 3. Baker, M. Fragment-based lead discovery grows up. ature Rev. Drug Discov. 12, 7 (213). 4. Morley, A.D. et al. Fragment-based hit identification: thinking in 3D. Drug Discovery Today. 18, 1221-1227 (213).. Jhoti,. et al. The rule of three for fragment-based drug discovery: where are we now? ature Reviews Drug Discovery 12(8), 644-64 (213). 6. Zartler, E.; Swain, C.; Pearce, S. Fragment library design: the evolution of fragment-based lead discovery. Drug Discovery World, 19-24 (Winter 212/13). 7. ajduk, P.J., Galloway, W.R.J.D., Spring, D.R. Drug discovery: A question of library design. ature 47, 42 43 (211). 8. ung, A.W. et al. Route to three-dimensional fragments using diversity-oriented synthesis. Proc. atl. Acad. Sci. USA. 18, 6799-684 (211). 9. Lovering, F., Bikker, J., umblet, C. Escape from flatland: Increasing saturation as an approach to improving clinical success. J. Med. Chem. 2, 672 676 (29). 1. Drysdale, M. J. Fragment-based drug discovery: the shape of things to come. Aust. J. Chem. 66, 144 149 (213). 11. ver, B. et al. atural-product-derived fragments for fragment-based ligand discovery. at. Chem., 21-28 (213).

12. Congreve, M., Carr, R., Murray, C., Jhoti,. A Rule of Three for fragment-based lead discovery. Drug Discov. Today 8, 876 877 (23). 13. Trepalin, S. V. et al. ew Diversity Calculations Algorithms Used for Compound Selection. J. Chem. Inf. Comput. Sci. 42, 249-28 (22). 14. W.. B. Sauer, M. K. Schwarz. Molecular shape diversity of combinatorial libraries: a prerequisite for broad bioactivity. J. Chem. Inf. Comput. Sci. 43, 987 (23).